Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the ...

Indian American physician to help accelerate commercial readiness for biotechnology firm’s cell therapy for Parkinson’s ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

This perspective argues that Parkinson’s disease may involve functional iron deficiency, where bioavailable iron is limited despite normal or elevated total iron in the brain. The authors propose that ...